Thursday, 27 January 2022

08.30 – 08.45  Registration
08.45 – 09.00  Introduction – Jan van Meerbeeck, BE and Annemiek Snoeckx, BE

Session 1: Update on lung cancer screening: did we make any further progress?
09.00 – 09.20  Two years after NELSON: Are there any further data on subgroup analyses or secondary endpoints? – Harry De Koning, NL
09.20 – 09.30  Status of current ERS driven lung cancer screening initiatives – David Baldwin, UK
09.30 – 09.40  Presentation of the ESTI Lung Cancer Certification Project - Annemiek Snoeckx, BE
09.35 – 10.00  Discussion

10.00 – 10.30  Coffee break

10.30 – 12.00  Break-out session I
What is currently ongoing in Europe?

- An update on current initiatives in different European countries
  Chairs: Jan van Meerbeeck
  6 minutes per speaker (according to a structured layout that will be delivered to the speakers)
  Europe; Croatia; UK; Italy; Germany; France; Norway; Spain; Poland
- How will smoking cessation be integrated into lung cancer screening in your lung cancer screening program?
  Chairs: tbc

12.00 – 12.30  Report to the plenary session and discussion

12.30 – 13.15  Lunch break

Session 2 - The time to implement is now
13.15 – 13.35  Making research findings more powerful for clinical use – Sabina De Geest, CH
13.35 – 13.55  Role of the GP in lung cancer screening – tbc
13.55 - 14.15  Psychological impact of lung cancer screening – Georgia Hardavella, GR
14.15 – 14.35  The voice of the participant – tbc
14.35 – 15.00  Discussion
15.00 – 16.30 Break out session 2: presentation of research projects in Europe

- **Group 1**: The quest for biomarkers for early lung cancer  
  Chair: Luis Montuenga and Joanna Chorostowska
- **Group 2**: ERS-task force on handling of screen detected nodules  
  Chair: David Baldwin and Witold Rzyman

16.30 – 17.00  **Coffee break**

**Session 3: The world does not stand still: evolution in imaging and treatment**

17.00 – 17.20  *Is ultra-low-dose ready for practice?* – Mario Silva, IT
17.20 – 17.40  *Research opportunities in nodule handling: robotic surgery and beyond* – Witold Rzyman, PL
17.40 – 18.00  *Artificial Intelligence in lung cancer screening* – Colin Jacobs, NL
18.00 – 18.30  Discussion

**Friday, 28 January 2022**

**Session 4: Early detection biomarkers: ready for implementation in screening?**

09.00 – 09.20  *Genomic screening: myths, promises and achievements* – Joanna Chorostowska, PL
09.20 – 09.40  *Biomarker performance and pathways to clinical utility* – Luis M. Montuenga, ES
09.40 – 10.00  *VOC’s for lung cancer screening: where are we now?* – Marc Van Der Schee, NL

10.00 – 10.30  Discussion
10.30 – 11.00  **Coffee break**

**11.00 – 12.00 Report from break out session II**

- Group 2 + discussion  20’
- Group 3 + discussion  20’

**Session 5: Taking research forward in the ERS**

12.00 – 12.20  *What is the optimal design for trials incorporating biomarkers and CT-scan screening?*  
  – tbc
12.20 – 12.40  *Agenda for an ERS clinical research collaboration* – Jan van Meerbeeck, BE
12.40 – 13.00  Remarks, wrap up and action points

13.00 – 14.00  Lunch

Meeting of the Task Force writing committee  
All speakers + all chairs